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Abstract 
Primary tamoxifen therapy has been widely used to treat elderly women with ER-
positive breast cancer in the past. Aromatase inhibitors may be more beneficial than 
tamoxifen when used as primary endocrine therapy in elderly patients. We aimed to 
retrospectively evaluate a series of elderly women with ER-positive breast cancer 
treated with primary letrozole therapy as sole therapy with a minimum of 5 years 
follow-up. To identify possible predictive biomarkers a pilot immunohistochemical 
analysis was performed to assess the expression of PR, HER2, EGFR, BCL2 and 
p53. 
A total of 45 women, aged more than 70 years with a diagnosis of ER-positive breast 
cancer that was treated with primary letrozole therapy were identified. A case note 
review was undertaken to obtain clinical information. Formalin fixed paraffin 
embedded tumour tissue from diagnostic core biopsies was available for all patients. 
Immunohistochemical analysis was performed to establish the protein expression 
status of p53, PR, HER2, EGFR and BCL2. 
The mean age of the 45 patients was 87 years (range 70-101). Clinical benefit was 
seen in 60% of the patients. Median progression free survival was 53 months (95% 
CI – 34 to 72) and the median time to progression was 43 months (95% CI – 22 to 
64). BCL2 was expressed in 45/45 (100%); PR in 38/45 (84%); EGFR in 13/45 
(28%); HER2 in 9/45 (20%) and p53 in 5/45 (11%) of tissue samples. Positive 
expression of p53 was associated with poor progression free survival (p=0.03) in this 
pilot study. 
This study demonstrates that letrozole as sole treatment appears to be a suitable 
treatment option for elderly patients with ER-positive breast cancer who are not fit for, 
or decline, surgery. The analysis of p53 in a larger study is warranted in order to 
assess its role as a biomarker in this patient group. 
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Introduction: 
Breast cancer is one of the most common cancers worldwide, with more than one 
third of them occurring in women over 70 years of age in the UK [1]. In this cohort 
(>70 years), breast cancer predominantly present as palpable cancers (mostly T2-4) 
and are frequently hormone receptor positive [2-7]. In the absence of clinical 
recommendations, treatment of women in this age group has often been based upon 
studies conducted in younger patients, since few women over the age of 65 are 
recruited into major trials [1, 7, 8].  
Primary tamoxifen therapy has been widely used to treat elderly women with ER-
positive breast cancer in the past. However, a recent Cochrane systematic review of 
6 randomized control trials (n=157; events 869) has shown that primary surgery (with 
or without adjuvant endocrine therapy) resulted in better progression free survival 
(PFS) compared to tamoxifen, but there was no difference in overall survival [9]. A 
randomized control trial in the UK comparing surgery plus tamoxifen versus 
tamoxifen alone in 455 women over 70 years of age with a median follow up of more 
than 12 years showed the surgery plus tamoxifen treatment arm to have longer time 
to treatment failure and improved survival (overall mortality and mortality from breast 
cancer) compared to tamoxifen alone [10]. The Italian phase III randomized GRETA 
trial compared surgery plus adjuvant tamoxifen (n=239) to primary tamoxifen alone 
(n=235) in women over 70 years of age with breast cancer and demonstrated no 
benefit in the overall survival or breast cancer survival, but improved rates of local 
progression in the surgery plus tamoxifen treatment arm compared to tamoxifen 
alone (p=0.0001) [11]. Further, the clinical results from three major trials (CRC, 
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GRETA and Nottingham 2 study) that looked into the role of surgery plus adjuvant 
endocrine treatment to primary endocrine treatment alone indicate the overall 
survival (OS) for the primary endocrine treatment is comparable to the surgery plus 
adjuvant treatment arm (Table 1).  
Aromatase inhibitors (AI’s) such as letrozole, anastrozole or exemestane may be 
more beneficial than tamoxifen when used as primary endocrine therapy in elderly 
patients. Letrozole has been shown to be beneficial in older patients in two large 
adjuvant trials, MA.17 and BIG 1-98 [12-14] and the use of AI’s for primary therapy in 
postmenopausal women with ER-positive breast cancer has also shown promising 
results in various trials (Table 2).  The P024 trial compared 4 months of pre-operative 
tamoxifen versus letrozole in post-menopausal women and demonstrated that the 
overall response to letrozole was significantly better than tamoxifen (55% versus 
36%; p=0.001) and resulted in increased breast-conserving surgery (45% versus 
35%; p=0.022) [15-16]. Other studies such as The IMPACT trial and the PROACT 
trial compared pre-operative treatment with anastrozole versus tamoxifen and 
showed that there was no statistically significant difference between anastrozole and 
tamoxifen in overall response and rates of breast-conserving surgery [17-18]. In a 
study of elderly patients with ER-positive breast cancer treated with either primary 
tamoxifen or anastrozole no significant difference in clinical benefit between the two 
groups was identified [19]. Two small phase II trials found that the use of exemestane 
as primary therapy was effective in post-menopausal women with ER-positive breast 
cancer and was a feasible therapy option for elderly patients [20-21]. Recent 
recommendations for the management of elderly breast cancer patients include the 
use of primary tamoxifen or AI therapy in unfit patients with short life expectancy or 
for those who refuse surgery [7]. 
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To further increase the efficacy of AI’s as primary or neoadjuvant treatment in breast 
cancer, the identification of predictive biomarkers of response and improved survival 
is paramount. In the P024 trial, letrozole showed similar efficacy when administered 
to patients with HER2-positive, HER2-negative, EGFR-positive and EGFR-negative 
tumours. However, ER-positive patients who demonstrated double positivity for 
EGFR and HER2 had higher response rates to letrozole therapy compared to 
patients who were double negative (88% versus 54%; p=0.018) [22]. In a similar 
study using anastrazole, HER2 status was not associated with response to treatment 
[23]. In another study of 305 patients, which included patients from the P024 study as 
well as from the Edinburgh Breast Unit, response to letrozole was seen irrespective 
of the HER2 status which was assessed by FISH [24]. In a study involving elderly 
patients treated with primary anastrazole treatment, HER2 positivity was associated 
with shorter PFS (p=0.003) whilst EGFR expression was not associated with survival 
[19]. Further data on the use of primary AI therapy in the treatment of elderly patients 
with ER-positive breast cancer is required.  
Aims of the Study: 
We aimed to retrospectively evaluate a series of elderly women with ER-positive 
breast cancer treated at our Breast Unit with primary letrozole therapy as sole 
therapy and with a minimum of 5 years follow-up. To further identify possible 
predictive biomarkers of response, a pilot immunohistochemical analysis was 
performed to assess the tumour expression of PR, HER2, EGFR, BCL2 and p53. 
 
Methods: 
Following approval by Hull and East Riding Research Ethics Committee, 
retrospective data was assessed from elderly patients (age >70 years) who had 
received primary letrozole therapy for ER-positive breast carcinoma between 2002 
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and 2004. Diagnostic core biopsies and clinical information was required for all 
patients. A case note review was undertaken to obtain information regarding tumour 
characteristics, response to therapy and disease progression. All patients had 
undergone triple assessment including clinical examination, mammogram, ultrasound 
scan and histological assessment of core biopsy samples to establish the diagnosis 
of breast cancer. Each case had been discussed at a multidisciplinary team meeting 
before patients were offered the treatment options. Primary letrozole therapy was 
employed for ER/PR positive elderly patients with significant co-morbidity or those 
who had declined surgery. All patients received clinical followed up at three monthly 
intervals and at the first sign of loss of local tumour control or metastases other 
treatment options had been discussed with the patient.  
Endocrine therapy: 
All elderly post-menopausal patients with early breast cancer not fit for surgery were 
treated with letrozole 2.5 mg daily as first line agent.  
Assessment of response: 
Clinical end points such as PFS, time to progression (TTP) and response rate were 
calculated. PFS was defined as the time from biopsy until tumour progression or 
death due to any cause. As a significant number of patients in this cohort had died 
due to causes unrelated to breast cancer TTP was also calculated and defined as the 
time from biopsy until tumor progression. Progressive disease was defined as an 
increase in the primary breast tumor size by clinical caliper examination of more than 
20% or development of metastatic disease. Clinical benefit was defined when tumour 
response or stable disease was achieved following treatment. 
Immunohistochemistry:  
Formalin fixed, paraffin embedded core biopsies taken at the time of breast cancer 
diagnosis were retrieved for 45 tumours. Immunohistochemical results for ER and 
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PR, performed at the time of diagnosis and scored according to the method of Allred 
[25], were obtained from histology reports. Immunohistochemical staining for BCL2, 
EGFR, HER2 and p53 was carried out using an avidin-biotin complex protocol 
described previously [26-27]. In brief, antigenic sites were retrieved by boiling in a 
1:100 Antigen Unmasking Solution (Vector Laboratories Ltd) in a pressure cooker for 
3 minutes at 15 psi. Non-specific binding was blocked with 1x casein (Vector 
Laboratories Ltd) and endogenous avidin and biotin were blocked by 15 minute 
incubations with biotin and avidin, respectively (Avidin Biotin Blocking Kit, Vector 
Laboratories Ltd). Sections were incubated at room temperature for 2 hours with 
primary antibody. A final dilution of 1:50 was used for BCL2 (#MS-123, Neomarkers) 
and EGFR (#MS-316, Neomarkers). A final dilution of 1:100 was used for p53 
(#554293, BD Biosciences). HER2 (#NCL-L-CBE-356, Novocastra Vision 
Biosystems) was used at 1:50 without heat retrieval. A negative control was also 
included in each batch of slides, in which the primary antibody was omitted. The 
slides were scored by 2 independent investigators. Sections were scored positive for 
p53 expression if strong clonal immunoreactivity was observed in greater than 10% 
of tumour nuclei and positive for the anti-apoptotic protein BCL2 if strong expression 
was seen in greater than 10% of tumour cytoplasm as previously described [27]. 
Similarly, sections were scored positive for EGFR and HER2 if strong 
cytoplasmic/membrane expression was observed in greater than 10% of malignant 
cells. 
Statistical analysis: 
Statistical analysis was performed using SPSS software version 19.0 (SPSS, 
Chicago, USA). PFS and TTP were estimated using Kaplan Meier curves. Univariate 
survival analysis was performed for biomarker expression using Kaplan Meier curves 
with log rank analysis. Fisher’s exact test was performed to assess biomarkers 
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predictive of response to letrozole. A two tailed p-value of <0.05 was considered to 
be statistically significant.  
 
Results: 
The patient characteristics in the study are described in the Figure 1. A total of 45 
patients’ core biopsies were analysed using IHC. This sample represents 3% 
(45/1450) of all the breast cancers treated at our institution during the three year 
study period. The median age of study patients was 87 years (range 70-101). Triple 
assessment revealed a clinical tumour stage T2 or greater in 66% (30/45) of cases. 
Histological characteristics revealed that the majority (57%; 26/45) of tumours were 
of non-specific subtype. Invasive ductal carcinoma represented 37% (17/45) of cases 
and invasive lobular carcinoma represented 4% (2/45) of cases.  
Follow-up, response and survival to primary letrozole therapy: 
All patients were followed up for a minimum of 5 years, with a median follow up 
period of 92 months (range 4–106 months). All patients during the FU were 
evaluated by clinical examination. Clinical benefit was seen in 60% (27/45) of the 
patients and 40% (18/45) of patients had progressed on letrozole therapy. At the end 
of last follow up, 68% (31/45) of the patients had died. The median PFS was 53 
months (95% CI – 34 to 72) and the median TTP was 43 months (95% CI – 22 to 
64).  
Molecular markers predicting response or improved survival to primary 
letrozole therapy: 
The expression of BCL2 was seen in 100% (45/45) of the tumour samples. The 
expression of PR was seen in 84% (38/45) of cases; EGFR in 28% (13/45); HER2 in 
20% (9/45) and p53 in 11% (5/45). In this pilot study p53 staining was used as a 
surrogate to identify p53 gene mutation. In a univariate analysis, the positive 
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expression of p53 was significantly found associated with a poor PFS (median 
survival 20 months versus 54 months in p53 negative; p=0.03; Figure 2). Clinical 
benefit was seen in only 1 out of 5 patients harbouring a p53-positive tumour. The 
expression of PR, EGFR and HER2 was not associated with survival. Correlation of 
protein expression with treatment response using Fishers exact test was not 
statistically significant.  
 
Discussion: 
In this study, we have described a series of 45 elderly patients with ER-positive 
breast cancer who were treated with primary letrozole therapy and followed up for a 
minimum period of 5 years. Our study demonstrated clinical benefit in 60% of the 
patients, with 40% having progressed on letrozole at last follow up or death. There 
are few published reports describing the clinical experience of using primary letrozole 
therapy in elderly breast cancer patients. A previous case series from the Edinburgh 
Breast Unit reported their findings from 182 post-menopausal patients, of whom 63 
had continued on primary letrozole therapy beyond 3 months [28]. The median follow 
up of this study was 3 years and disease control was achieved in over 70% of the 63 
patients using letrozole. Another recently published retrospective study evaluated the 
overall survival and response rate of 104 elderly patients with ER/PR-positive breast 
cancer who were treated with primary letrozole therapy [16]. Some of the earlier 
described studies using tamoxifen as the primary hormone therapy showed disease 
progression and poor survival after two years even in patients who initially responded 
to treatment. In contrast, findings from our study showed only one patient progressed 
within the first year and four more within two years of commencing treatment (11%; 
5/45).  
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Previously, breast cancer studies in elderly evaluated the role of p53, HER2 and 
EGFR as potential biomarkers of therapy responses and prognosis with trends 
towards less frequent overexpression of biomarkers favouring an improved survival 
and more desirable tumour biology (5, 22, 24, 29, 30). Our pilot study showed similar 
trend of low frequency of overexpression of these protein markers. Previously, HER2 
positivity has been demonstrated to associate with shorter PFS in elderly patients 
who received primary anastrazole therapy [19]. However, in our pilot study, we found 
p53 expression as a surrogate for mutation status which was found to be associated 
with poor PFS. From the above findings, we hypothesise that if validated further, p53 
may be useful in screening patients for primary letrozole therapy. Mutations in p53 
may result in a stable p53 protein that can be identified by immunohistochemistry, 
however not all mutations are associated with stabilised protein [31]. Further studies 
using DNA sequencing-based methods, may therefore also be required to assess 
p53 mutation status in order to validate the effect of p53 mutation on PFS in patients 
treated with letrozole as primary therapy.  
The study however has certain limitations. For a study of an exploratory nature, the 
included patient sample in the study is small and has a potential to impact on the 
study power. However, despite the above limitation, a clear statistical difference was 
detected in the study for p53 responder group versus the non- responders. The three 
other biomarkers (BcL-2, EGFR and HER2) explored in the study however, failed to 
reach a statistical difference in the responder group. This may well be due to a type 2 
statistical error from a limited sample of patients analysed in the study. Further, 
authors acknowledge that the non-availability of biopsy material in 35% (24/69) of 
potentially eligible patients preclude the ability of the study to recommend the use 
p53 as a screening tool. Lastly, only a small proportion of patients (0.3%; 5/1450; 
11% of 3%) from the study group were shown to benefit from using p53 as a therapy 
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biomarker, larger studies evaluating the role of p53 in primary endocrine therapy 
patient selection are therefore now required. 
Conclusion: 
In conclusion, our pilot study demonstrated that the positive expression of p53 was 
associated with poor PFS in patients treated with primary letrozole therapy. This 
biomarker may be used as a useful screening tool to select patients who would 
benefit from primary letrozole therapy. 
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Table 1:  Surgery plus adjuvant endocrine therapy vs primary endocrine therapy 
Trial Median Follow up Surgery 
(n/N) 
Primary Endocrine Therapy 
(n/N) 
HR (95% CI) 
Surgery plus endocrine therapy vs primary endocrine therapy 
Mortality (OS) 
CRC 
GRETA 
Nottingham 2 
13 years 
7 years 
5 years 
159/225 
130/239 
8/53 
187/230 
144/235 
14/94 
0.78 (0.63-0.98) 
 0.98 (0.77 -1.25) 
0.80 (0.73-2.32) 
Progression Free survival (PFS) 
CRC 
GRETA 
Nottingham 2 
13 years 
7 years 
5 years 
NR 
14/239 
NR 
NR 
188/235 
NR 
NR 
0.65 (0.53-0.81) 
NR 
Local Progression (LR) or LR as first 
event 
CRC 
GRETA 
Nottingham 2 
13 years 
7 years 
5 years 
36/225 
27/239 
2/53 
115/230 
95/235 
30/94 
0.25 (0.19-0.32) 
0.38 (0.25-0.57) 
Not estimable 
Table 1: The above table summarises the findings of surgery plus adjuvant endocrine treatment versus primary endocrine 
treatment alone from the three important randomised controlled trials. In all the three trials, the overall survival (OS) for the primary 
endocrine treatment arm was found similar to surgery and adjuvant treatment arm (Hind D et al. Br J Cancer. 2007 Apr 10; 
96(7):1025-9) 
Table 2: Aromatase Inhibitor Trials 
Table 2: The above table shows findings from the four major aromatase inhibitor trials namely P024, IMPACT, PROACT and Semiglazov 
study. Of the four trials, three compared anastrozole with standard tamoxifen and/or chemotherapy treatment and one trial compared letrozole 
Trial Patient 
Number 
(n) 
        Comparator ORR BCS 
 P024  
(Eiermann 2001) 
n= 337 Letrozole Tamoxifen  55% vs 36% 
P= <0.001  
45% vs 35% 
P = 0.022  
IMPACT 
(Smith 2005) 
n= 330 Anastrazole Tamoxifen  37% vs 36% 
P= 0.87  
44% vs 31% 
P= 0.23 
PROACT (Cataliotti 
2006) 
n=451 Anastrazole Tamoxifen  40% vs 35% 
P= 0.29 
38% vs 30% 
P= 0.11 
(Semiglazov 2007) n=239 Anastrazole / Exemestane Chemotherapy  65% vs 64% 
P= >0.5 
33% vs 24% 
P= 0.58 
with tamoxifen for attainment of objective response (ORR) and breast conserving surgery (BCS) rates. Findings from the studies clearly 
demonstrate letrozole to be the superior therapy to attain ORR and BCS rates compared to other AIs and chemotherapy. 
Figure 1:  THE STUDY CONSORT 
Figure 1: 
Consort chart for the pilot study showing a total of 110 patients who were treated 
with letrozole as primary therapy as identified from the prospectively maintained 
chemotherapy database. After case-note review, 41 patients were excluded from the 
study as they had metastatic disease at presentation, refused follow-up after their 
first visit or they chose early surgery without completing the treatment course. Of the 
69 remaining patients, 45 patients had core biopsy samples available for 
assessment. 
Total number of patients 
treated with Letrozole 
during the study period 
n=110 
Total number of patients 
excluded from the study 
due to cancer 
progression, refused FU 
or offered early surgery 
n=41 (37.2%) 
Total number of 
patients included in the 
study n=69 (62.7%) 
Total number of core 
biopsies available for IHC 
analysis n=45 (65%) 
Figure 2: Kaplan Meier plot showing univariate analysis of p53 
expression (p=0.03, log rank). The median survival was 20 months in 
p53-positive cases (n=5; dotted line) versus 54 months for p53-negative 
cases (n=40; solid line).  
